Citigroup Cuts Tandem Diabetes Care Price Target Amid Mixed Analyst Sentiment

Citigroup reduced its price target for Tandem Diabetes Care from $24 to $20 while maintaining a neutral rating on the medical device manufacturer. The company reported quarterly revenue of $254.6 million, reflecting 5.8% year-over-year growth, and an adjusted loss of $0.31 per share that marginally beat expectations. Analyst sentiment remains divided with a hold consensus rating and a mixed outlook despite recent target reductions from multiple research firms.

Tandem Diabetes Care faces growing headwinds reflected in consecutive price target cuts from major financial institutions. Beyond Citigroup's reduction, both Mizuho and Royal Bank of Canada have similarly lowered their outlooks in recent weeks, though the company's operational performance shows modest improvement—revenue growth accelerated to 5.8% annually while earnings losses narrowed significantly compared to the prior year period.

The divergence in analyst recommendations underscores uncertainty about the company's trajectory. While some firms maintain bullish positions citing market potential, the consensus rating of "Hold" with an average target substantially above current trading levels suggests analysts expect limited near-term momentum. The medical device manufacturer's elevated debt-to-equity ratio of 4.62 may constrain financial flexibility as it pursues profitability.